




RealRate

PHARMACEUTICAL 2013

AVEO Pharmaceuticals INC
Rank 64 of 218



The relative strengths and weaknesses of AVEO Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of AVEO Pharmaceuticals INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 131% points. The greatest weakness of AVEO Pharmaceuticals INC is the variable Research and Development, reducing the Economic Capital Ratio by 23% points.

The company's Economic Capital Ratio, given in the ranking table, is 306%, being 86% points above the market average of 220%.

Input Variable	Value in 1000 USD
Assets, Current	190,681
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	39,130
Liabilities, Non-Current	0
Other Assets	3,921
Other Compr. Net Income	148
Other Expenses	2,633
Other Liabilities	0
Other Net Income	-2,757
Other Revenues	19,286
Property and Equipment	12,867
Research and Development	91,358
Selling, General and Administrative Expense	36,932

Output Variable	Value in 1000 USD
Assets	207,469
Liabilities	39,130
Expenses	130,923
Revenues	19,286
Stockholders Equity	168,339
Net Income	-114,394
Comprehensive Net Income	-114,320
BaseVar	199,856
ECR before LimitedLiability	205%
Economic Capital Ratio	306%